KYKOF - Kyowa Kirin Co., Ltd.
| Previous close | 21.54 |
| Open | 21.88 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 21.54 - 21.54 |
| 52-week range | 20.87 - 23.85 |
| Volume | |
| Avg. volume | 538 |
| Market cap | 11.577B |
| Beta (5Y monthly) | 0.14 |
| PE ratio (TTM) | 32.15 |
| EPS (TTM) | 0.67 |
| Earnings date | N/A |
| Forward dividend & yield | 0.41 (1.90%) |
| Ex-dividend date | 29 Jun 2023 |
| 1y target est | N/A |
CNW GroupKyowa Kirin North America Assumes Commercial Leadership Role for (Pr)CRYSVITA™ (Burosumab Injection) in North America
Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a top 50 global specialty pharmaceutical company, today assumes primary commercial leadership for PrCRYSVITA™ (burosumab injection) in the United States and Canada from Ultragenyx Pharmaceutical, Inc., a transition planned for from the start of their decade-long collaboration. Initially discovered and developed by Kyowa Kirin, CRYSVITA is used for the treatment of X-linked hypophosphataemia (XLH) in adult and pedi
- Business Wire
MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting
SAN DIEGO & TOKYO, December 05, 2022--MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that after receiving the most recent guidance from a late November meeting with the U.S. Food and Drug Administration (FDA), the companies are discontinuing glob
- Business Wire
Grünenthal and Kyowa Kirin International Announce Joint Venture Collaboration for Established Medicines Portfolio
AACHEN, Germany & TOKYO, November 24, 2022--Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and Grünenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company, are today announcing they have signed a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio. The Joint Venture Collaboration comprises 13 brands across 6 therapeutic
- Business Wire
MEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for Presentation at the American Society of Hematology Annual Meeting 2022
SAN DIEGO & TOKYO, November 03, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that three abstracts highlighting data and information from the clinical development program evaluating the intermittent dosing of zandelisib, an investigational
- Business Wire
MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy
SAN DIEGO & TOKYO, July 18, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced publication of data from the Phase 1b clinical study of zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta ("PI3Kδ") inhibitor, in
Business WireMEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress
SAN DIEGO & TOKYO, June 10, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that data from the zandelisib clinical development program, including the Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an orally administered
Business WireMEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022
SAN DIEGO & TOKYO, June 04, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced data from the ongoing Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta